Trials / Conditions / HER-2 Gene Amplification

HER-2 Gene Amplification

14 registered clinical trials studyying HER-2 Gene Amplification.

Status	Trial	Sponsor	Phase
Terminated	Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors NCT05511844	Orum Therapeutics USA, Inc.	Phase 1
Unknown	A Study of Trastuzumab and Pyrotinib in HER2 Positive Locally Advanced or Metastatic Urothelial Carcinoma NCT05318339	Chinese Academy of Medical Sciences	Phase 2
Unknown	Trastuzumab and Standard Treatment With Chemo- and Immunotherapy as First Line Treatment for HER2 Positive Eso NCT05170256	Morten Mau-Sørensen	Phase 2
Active Not Recruiting	CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors NCT04660929	Carisma Therapeutics Inc	Phase 1
Suspended	Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive So NCT04650451	Bellicum Pharmaceuticals	Phase 1
Unknown	Trastuzumab Biosimilar (Samfenet®) Plus Treatment of Physician's Choice (TPC) in Patients With HER2-positive S NCT04215159	Jin-Hee Ahn	Phase 2
Unknown	The Basket Study of Pyrotinib Maleate for HER2-Postive Solid Tumor NCT04179656	Tianjin Medical University Second Hospital	Phase 2
Completed	Trastuzumab in HER2-positive Biliary Tract Cancer NCT03613168	Changhoon Yoo	Phase 2
Completed	Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas NCT03783936	Ashwin Somasundaram	Phase 2
Unknown	Evaluation of Pertuzumab-Trastuzumab and Taxane in the Standard Treatment of Metastatic Breast Cancer NCT03979911	University Hospital, Brest	—
Terminated	Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1 NCT03630809	H. Lee Moffitt Cancer Center and Research Institute	Phase 2
Completed	Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Ge NCT03602079	Klus Pharma Inc.	Phase 1 / Phase 2
Terminated	A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus NCT01774851	Merrimack Pharmaceuticals	Phase 2
Completed	A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer NCT01304784	Merrimack Pharmaceuticals	Phase 1